MedTrace Logo

Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm

NCT03254004 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2020-12-14

No results posted yet for this study

Summary

A single center, open-label, single arm study in patients who have solid or micropapillary adenocarcinoma with pathologic stage I and primary tumor no more than 4 cm. Pembrolizumab 200 mg every 3 weeks

Conditions

  • Lung Adenocarcinoma, Stage I

Interventions

DRUG

Pembrolizumab

pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • jhingook Kim, MD · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-08
Primary Completion
2021-03-30
Completion
2021-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03254004 on ClinicalTrials.gov